Efficacy of High Dose Tranexamic Acid in Decreasing Bleeding after Cardiac Surgery for Cyanotic Congenital Heart Disease in Children Less than Ten Kilo Body Weight
Background: To determine the effect of high dose tranexamic acid in decreasing immediate postoperative bleeding in children less than ten kilo body weight after complex cardiac surgery and also to evaluate the safety of high dose in small children. Methods: Between January-December 2015, 25 children weighing less than ten kilogram body weight underwent complex cardiac surgery for cyanotic congenital heart disease. All children were given dose of 100 mg/kg tranexamic acid at the time of anaesthetic induction and also 100 mg/kg into the CPB prime. The Median age and weight was 80 days (3 - 365) and 4.69 kg (2.4 - 7.8) respectively. The Median preoperative Hb was 10 g/dl (9.6 - 19.5 g/dl). Cardiac surgery included total intracardiac repair for TOF in 10 pts (40%), TAPVC repair in 6 (24%), arterial switch operation in 6 pts (24%), BD glenn in 1, repair of DORV with VSD in 1 and VSD closure with scimitar vein reimplantation in 1 pt. Median CPB time was 127 minutes (97 - 343) and cross clamp time was 99 (67 - 200) minutes. Moderate to deep hypothermia was maintained in all with median temperature of 24°C (18 - 32). Three children (12%) had elective open chest in view of anticipated bleeding. Results: The Median postoperative drainage was 127 ml, (range 10 - 1250 ml). The median postoperative use of whole blood was 95 ml (range 10 - 275), packed cell was 187 ml (range 50 - 400 ml), frozen plasma was 88 ml (range 30 - 170), platelet concentrate was 57 ml, (range 10 - 100 ml) and cryoprecipitate was median 47.5 ml, (range 30 - 80 ml). No neurological dysfunction and renal dysfunction has been observed in any of the pts. Out of 4 mortalities (16%), only one was attributed to bleeding (4%) due to usage of ECMO. No late neurological or renal dysfunction has been observed in remaining 21 pts on follow up. Conclusion: High dose Tranexamic acid can be safely used in small children during complex cardiac surgery with significant reduction in postoperative bleeding and blood product usage without any higher incidence of neurological, renal dysfunction or myocardial infarction.
References
[1]
Dunn, C.J. and Goa, K.L. (1999) Tranexamic Acid: A Review of Its Use in Surgery and Other Indications. Drugs, 57, 1005-1032. https://doi.org/10.2165/00003495-199957060-00017
[2]
Faraoni, D., Willems, A., Melot, C., De Hert, S. and Van der Linden, P. (2012) Efficacy of Tranexamic Acid in Paediatric Cardiac Surgery: A Systematic Review and Meta-Analysis. European Journal of Cardio-Thoracic Surgery, 42, 781-786. https://doi.org/10.1093/ejcts/ezs127
[3]
Zonis, Z., Seear, M., Reichert, C., Sett, S. and Allen, C. (1996) The Effect of Preoperative Tranexamic Acid on Blood Loss after Cardiac Operations in Children. The Journal of Thoracic and Cardiovascular Surgery, 111, 982-987. https://doi.org/10.1016/S0022-5223(96)70374-4
[4]
Reid, R.W., Zimmerman, A.A., Laussen, P.C., Mayer, J.E., Gorlin, J.B. and Burrows, F.A. (1997) The Efficacy of Tranexamic Acid versus Placebo in Decreasing Blood Loss in Pediatric Patients Undergoing Repeat Cardiac Surgery. Anesthesia & Analgesia, 84, 990-996. https://doi.org/10.1213/00000539-199705000-00008
[5]
Ker, K., Edwards, P., Perel, P., Shakur, H. and Roberts, I. (2012) Effect of Tranexamic Acid on Surgical Bleeding: Systematic Review and Cumulative Meta-Analysis. BMJ, 344, e3054. https://doi.org/10.1136/bmj.e3054
[6]
Chauhan, S., Bisoi, A., Kumar, N., Mittal, D., Kale, S., Kiran, U., et al. (2004) Dose Comparison of Tranexamic Acid in Pediatric Cardiac Surgery. Asian Cardiovascular and Thoracic Annals, 12, 121-124. https://doi.org/10.1177/021849230401200208
[7]
Shimizu, K., Toda, Y., Iwasaki, T., et al. (2011) Effect of Tranexamic Acid on Blood Loss in Pediatric Cardiac Surgery: A Randomized Trial. Journal of Anesthesia, 25, 823-830. https://doi.org/10.1007/s00540-011-1235-z
[8]
Schindler, E., Photiadis, J., Sinzobahamvya, N., Dores, A., Asfour, B. and Hraska, V. (2011) Tranexamic Acid: Analternative to Aprotininas Antifibrinolytic Therapy in Pediatric Congenital Heart Surgery. European Journal of Cardio-Thoracic Surgery, 39, 495-499. https://doi.org/10.1016/j.ejcts.2010.07.026
[9]
Lin, C.-Y., Shuhaiber, J.H., Loyola, H., Liu, H., del Nido, P., DiNardo, J.A., et al. The Safety and Efficacy of Antifibrinolytic Therapy in Neonatal Cardiac Surgery. PLoS ONE, 10, e0126514. https://doi.org/10.1371/journal.pone.0126514
[10]
Bahnson, H. and Ziegler, R. (1950) A Consideration of the Causes of Death Following Operation for Congenital Heart Disease of the Cyanotic Type. Surgery, Gynecology & Obstetrics, 90, 60-76.
[11]
Gill, J.C., Wilson, A.D., Endres-Brooks, J. and Montgomery, R.R. (1986) Loss of the Largest von Willebrand Factor Multimer from the Plasma of Patients with Congenital Cardiac Defects. Blood, 67, 758-761.
[12]
Stammers, A.H., Rauch, E.D., Willett, L.D., Newberry, J.W. and Duncan, K.F. (2000) Pre-Operative Coagulopathy Management of a Neonate with Complex Congenital Heart Disease: A Case Study. Perfusion, 15, 161-168. https://doi.org/10.1177/026765910001500212
[13]
McMullan, V. and Alston, R.P. (2010) The Effect of the Suspension of the License for Aprotinin on the Care of Patients Undergoing Cardiac Surgery: A Survey of Cardiac Anesthesiologists’ and Surgeons’ Opinions in the United Kingdom. Journal of Cardiothoracic and Vascular Anesthesia, 24, 418-421. https://doi.org/10.1053/j.jvca.2009.10.028
[14]
Sniecinski, R.M., Chen, E.P., Makadia, S.S., Kikura, M., Bolliger, D. and Tanaka, K.A. (2010) Changing from Aprotinin to Tranexamic Acid Results in Increased Use of Blood Products and Recombinant Factor VIIa for Aortic Surgery Requiring Hypothermic Arrest. Journal of Cardiothoracic and Vascular Anesthesia, 24, 959-963. https://doi.org/10.1053/j.jvca.2010.02.018
[15]
Strouch, Z., Drum, M. and Chaney, M. (2009) Aprotinin Use during Cardiac Surgery: Recent Alterations and Effects on Blood Product Utilization. Journal of Clinical Anesthesia, 21, 502-507. https://doi.org/10.1016/j.jclinane.2008.12.021
[16]
Breuer, T., Martin, K., Wilhelm, M., Wiesner, G., Schreiber, C., Hess, J., Lange, R. and Tassani, P. (2009) The Blood Sparing Effect and the Safety of Aprotinin Compared to Tranexamic Acid in Paediatric Cardiac Surgery. European Journal of Cardio-Thoracic Surgery, 35, 167-171. https://doi.org/10.1016/j.ejcts.2008.09.038
[17]
de Leede-van der Maarl, M.G., Hilkens, P. and Bosch, F. (1999) The Epileptogenic Effect of Tranexamic Acid. Journal of Neurology, 246, 843. https://doi.org/10.1007/s004150050466
[18]
Hui, A.C., Wong, T.Y., Chow, K.M. and Szeto, C.C. (2003) Multifocal Myoclonus Secondary to Tranexamic Acid. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 547. https://doi.org/10.1136/jnnp.74.4.547
[19]
Martin, K., Wiesner, G., Breuer, T., Lange, R. and Tassani, P. (2008) The Risks of Aprotinin and Tranexamic Acid in Cardiac Surgery: A One-Year Follow-Up of 1188 Consecutive Patients. Anesthesia & Analgesia, 107, 1783-1790. https://doi.org/10.1213/ane.0b013e318184bc20
[20]
Hardy, J., Belisle, S., Dupont, C., Harel, F., Robitaille, D., Roy, M. and Gagnon, L. (1998) Prophylactic Tranexamic Acid and Epsilon-Aminocaproic Acid for Primary Myocardial Revascularization. The Annals of Thoracic Surgery, 65, 371-376. https://doi.org/10.1016/S0003-4975(97)01016-3
[21]
Katsaros, D., Petricevic, M., Snow, N.J., Woodhall, D.D. and Van Bergen, R. (1996) Tranexamic Acid Reduces Post-Bypass Blood Use: A Double-Blinded, Prospective, Randomized Study of 210 Patients. The Annals of Thoracic Surgery, 61, 1131-1135. https://doi.org/10.1016/0003-4975(96)00022-7
[22]
Karski, J.M., Teasdale, S.J., Norman, P., Carroll, J., VanKessel, K., Wong, P. and Glynn, M.F. (1995) Prevention of Bleeding after Cardiopulmonary Bypass with High-Dose Tranexamic Acid. Double-Blind, Randomized Clinical Trial. The Journal of Thoracic and Cardiovascular Surgery, 110, 835-842. https://doi.org/10.1016/S0022-5223(95)70118-4
[23]
Brown, J.R., Birkmeyer, N.J. and O’Connor, G.T. (2007) Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery. Circulation, 115, 2801-2813. https://doi.org/10.1161/CIRCULATIONAHA.106.671222
[24]
Henry, D., Carless, P., Fergusson, D. and Laupacis, A. (2009) The Safety of Aprotinin and Lysine-Derived Antifibrinolytic Drugs in Cardiac Surgery: A Meta-Analysis. CMAJ, 180, 183-193. https://doi.org/10.1503/cmaj.081109
[25]
Ngaage, D.L. and Bland, J.M. (2010) Lessons from Aprotinin: Is the Routine Use and Inconsistent Dosing of Tranexamic Acid Prudent? Meta-Analysis of Randomised and Largematched Observational Studies. European Journal of Cardio-Thoracic Surgery, 37, 1375-1383. https://doi.org/10.1016/j.ejcts.2009.11.055
